Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORVUS PHARMACEUTICALS, INC.

(CRVS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CORVUS PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

06/16/2021 | 04:07pm EDT

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 15, 2021, Corvus Pharmaceuticals, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). Only stockholders of record at the close of business on April 19, 2021, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, there were 38,309,551 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 27,719,139 shares of the Company's common stock were voted in person or by proxy for the two proposals set forth below, each of which is described in the Company's Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 20, 2021.

The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal No. 1 - Election of Directors

The Company's stockholders elected the Class II director nominees below to the Company's Board of Directors to hold office until the 2024 Annual Meeting of Stockholders or until their respective successors are elected and qualified or appointed, or the earlier of their death, resignation or removal.



Class II Director Nominees   Votes For    Votes Withheld   Broker Non-Votes
Scott W. Morrison            20,548,120      169,572          7,001,447
Edith P. Mitchell, M.D.      20,572,477      145,215          7,001,447




Proposal No. 2 - Ratification of Selection of Independent Registered Accounting Firm

The Company's stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.




Votes For    Votes Against   Abstain
27,550,167      47,149       121,823

© Edgar Online, source Glimpses

All news about CORVUS PHARMACEUTICALS, INC.
07/16CORVUS PHARMACEUTICALS : HC Wainwright Adjusts Corvus Pharmaceuticals' Price Tar..
MT
07/16SECTOR UPDATE : Health Care Stocks Eke Out Small Gains In Premarket Friday
MT
07/16UPDATE : Corvus Pharma Discontinues Phase 3 COVID-19 Study as Serious Infections..
MT
07/16NORTH AMERICAN MORNING BRIEFING : Retail Sales Awaited; Intel in Focus Amid M&A
DJ
07/15CORVUS PHARMACEUTICALS : Discontinues Phase 3 COVID-19 Study as Serious Infectio..
MT
07/15CORVUS PHARMACEUTICALS : Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) f..
PU
07/15CORVUS PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, Ot..
AQ
07/15Corvus Pharmaceuticals, Inc. Discontinues Phase 3 Study of Mupadolimab (Anti-..
CI
07/15CORVUS PHARMACEUTICALS : Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) f..
AQ
06/25CORVUS PHARMACEUTICALS, INC.(NASDAQG : CRVS) dropped from Russell Microcap Growt..
CI
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 -45,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,83x
Yield 2021 -
Capitalization 80,1 M 80,1 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 1,50x
Nbr of Employees 42
Free-Float 87,1%
Chart CORVUS PHARMACEUTICALS, INC.
Duration : Period :
Corvus Pharmaceuticals, Inc. Technical Analysis Chart | CRVS | US2210151005 | MarketScreener
Technical analysis trends CORVUS PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 2,09 $
Average target price 6,50 $
Spread / Average Target 211%
EPS Revisions
Managers and Directors
Richard A. Miller Chairman, President & Chief Executive Officer
Leiv Lea Chief Financial Officer
Mehrdad Mobasher Chief Medical Officer & Senior Vice President
Peter A. Thompson Independent Director
Elisha P. Gould Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CORVUS PHARMACEUTICALS, INC.-41.29%80
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907